MSC-treated groups compared with the control group (Figure 3E). The capillaries-to-muscle-fiber ratio of ischemic muscle at day 5 after transplantation was significantly increased in the amnion and chorion MSC groups (amnion MSCs: 1.53 ± 0.03/muscle fiber; $p<0.001$, chorion MSCs: 1.51 ± 0.04/muscle fiber; $p<0.001$) compared with the control group (1.05 ± 0.06/muscle fiber; Figure 3F). At day7, the capillaries-to-muscle-fiber ratio of ischemic muscle was also increased in the amnion or chorion MSC-transplanted mice (amnion MSCs: 1.67 ± 0.17/muscle fiber, chorion MSCs: 1.43 ± 0.09/muscle fiber) compared to the control mice (1.36 ± 0.11/muscle fiber).

Immunosuppressive Property of Human FM-MSCs

Although the number of T cells was markedly increased under proliferating conditions of human CD4+ T cells stimulated with anti-CD3 and -CD28 antibodies, the increase was significantly suppressed when co-cultured with amnion-, chorion-, or bone marrow-derived MSCs ($61.1\pm1.8\%$, $54.6\pm3.0\%$, $74.0\pm2.1\%$, respectively. $p<0.001$ vs. control) (Figure 4A).

PGE2 is a well-known immune modulator in bone marrow MSCs [13] and we confirmed that amnion MSCs in culture secreted a significant amount of PGE2 (29.7 ± 7.8 ng/10^6 cells), particularly when co-cultured with human CD4+ T cells (613.1 ± 139.9 ng/10^6 cells; $p<0.01$ vs. amnion MSCs) (Figure 4B). In chorion MSCs, however, the concentration of PGE2 was relatively low (0.77 ± 0.13 ng/10^6 cells) but significantly increased in co-culture with CD4+ T cells (4.76 ± 0.47 ng/10^6 cells; $p<0.001$ vs. chorion MSCs). The experiments were repeated with two or three independent MSC/CD4+ T cell donor pairs and the data are presented as the measured mean levels.

In addition, to evaluate the potential of FM-MSCs to suppress acute GVHD, mice underwent allogeneic hematopoietic stem cell transplantation and treatment with human FM-MSCs. As shown in Figure 4C, the loss in body weight of recipient mice after allogeneic hematopoietic stem cell transplantation was significantly reduced with concomitant transplantation of human amnion-derived MSCs. In human chorion MSC-transplanted group, however, no significant changes in body weight was observed during the observation period (Figure 4D).

Discussion

Human MSCs derived from bone marrow or adipose tissue exert a regenerative effect in animal models and human patients [14]. In addition, several reports have described the therapeutic potential of transplanted cells derived from the appendages of the fetus, including amniotic epithelium cells [15], and amniotic fluid- [16], amnion-, and chorion-derived MSCs [17,18]. We have previously demonstrated the therapeutic potential of rat FM-MSCs using various rat models including hindlimb ischemia, autoimmune myocarditis, glomerulonephritis, renal ischemia-reperfusion injury, and myocardial infarction [3–8]. Recent studies including ours also revealed the angiogenic and immuno-suppressive property of human fetal appendage-derived MSCs [14,18–20], but comparative studies of the therapeutic effects among these MSCs are lacking. Therefore, in this study, we examined the differences in the cellular function and therapeutic properties between human FM-derived amnion and chorion MSCs.

It is known that MSCs exert their regenerative effects through differentiation into specific cell types, but recent studies suggest that their ability to stimulate regenerative effects is mainly induced via paracrine effects [3,4,8,21]. This theory is substantiated by several reports that MSCs secrete various growth factors and cytokines including VEGF, IGF-1, HGF, adrenomedullin (AM), and PGE2 [3–5,8,21,22]. In this study, we first confirmed that chorion MSCs as well as amnion MSCs secreted significant amount of these soluble factors, which would contribute to accelerating regenerative effects. Compared with chorion MSCs, amnion MSCs secreted significantly larger amounts of HGF and bFGF. However, amnion MSCs secreted less IGF-1 compared to chorion MSCs. We assume that these differences in the cytokine expression profile might reflect the angiogenic and cytoprotective properties of amnion and chorion MSCs, as we observed difference in the effect on endothelial cells and cardiomyocytes in our conditioned-medium analysis. However, the actual function of amnion or chorion MSC-derived cytokines should be further investigated in vivo because both human amnion and chorion MSC transplantation similarly induced angiogenesis in the hindlimb ischemia model.

Previous reports have shown that PGE2 is a major modulator of the MSC-induced anti-inflammatory response [13]. In this study, a noteworthy finding was a distinctly high concentration of PGE2 in amnion MSCs in comparison with chorion MSCs, particularly when co-cultured with CD4+ T cells. Because of their high PGE2 production, human amnion MSCs might be a better cell source from an immunosuppressive point of view. In fact, we proved for the first time that human amnion MSCs, but not chorion MSCs, improved the pathological situation of an acute GVHD model. Because our previous study demonstrated that human amnion MSCs markedly inhibited differentiation as well as proliferation of Th1/Th17 cells [6], human amnion MSCs could effectively suppress Th1/Th17 immunity and improve outcome in GVHD.

The merit of using FMs lies in that they are free form ethical concern and that a large number of MSCs can be obtained considering the size of FM. As more than one or ten million MSCs per gram of the amnion or chorion could be obtained, more than 10^9 or 10^{10} MSCs could theoretically be obtained at passage 3 within one month, respectively. Now we are planning to initiate clinical studies with human amnion MSCs in acute GVHD and Crohn's disease, and we need more than 10^{10} MSCs for the treatment of one patient. We are convinced that human FM-MSCs are an attractive source for cell therapy because of their easy availability compared with other somatic, embryonic stem, and iPS cells.

In conclusion, both amnion and chorion MSCs have angiogenic, cytoprotective, and immunomodulatory effects. Because of high PGE2 production and immunosuppressive properties, human amnion MSCs have the advantage for the treatment of immune-related diseases. In addition, since a large number of MSCs could be obtained from FMs, human amnion and chorion MSCs would be a useful cell source for regenerative medicine.

Author Contributions

Conceived and designed the experiments: KY AT TS HO JY MHS KK TI. Performed the experiments: KY KH MO SI SO HT KO SK JY TI. Analyzed the data: KY KH MO TI. Contributed reagents/materials/analysis tools: KY KH MO TI. Wrote the paper: KY KH MO TI.

References

1. Prockop DJ (1997) Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276: 71–74.

2. Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, et al. (2002) Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 13: 4279–4295.

— 234 —

3. Ishikane S, Ohnishi S, Yamahara K, Sada M, Harada K, et al. (2008) Allogeneic injection of fetal membrane-derived mesenchymal stem cells induces therapeutic angiogenesis in a rat model of hind limb ischemia. Stem Cells 26: 2625–2633.
4. Ishikane S, Yamahara K, Sada M, Harada K, Kodama M, et al. (2010) Allogeneic administration of fetal membrane-derived mesenchymal stem cells attenuates acute myocarditis in rats. J Mol Cell Cardiol 49: 753–761.
5. Tsuda H, Yamahara K, Ishikane S, Otani K, Nakamura A, et al. (2010) Allogenic fetal membrane-derived mesenchymal stem cells contribute to renal repair in experimental glomerulonephritis. Am J Physiol Renal Physiol 299: F1004–1013.
6. Ohshima M, Yamahara K, Ishikane S, Harada K, Tsuda H, et al. (2012) Systemic transplantation of allogenic fetal membrane-derived mesenchymal stem cells suppresses Th1 and Th17 T cell responses in experimental autoimmune myocarditis. J Mol Cell Cardiol 53: 420–428.
7. Tsuda H, Yamahara K, Otani K, Okumi M, Yazawa K, et al. (2013) Transplantation of allogenic fetal membrane-derived mesenchymal stem cells protect against ischemia-reperfusion-induced acute kidney injury. Cell Transplant.
8. Ishikane S, Hosoda H, Yamahara K, Akitake Y, Kyoungsook J, et al. (2013) Allogeneic Transplantation of Fetal Membrane-Derived Mesenchymal Stem Cell Sheets Increases Neovascularization and Improves Cardiac Function after Myocardial Infarction in Rats. Transplantation.
9. Portmann-Lanz CB, Schoeberlein A, Huber A, Sager R, Malek A, et al. (2006) Placental mesenchymal stem cells as potential autologous graft for pre- and perinatal neuroregeneration. Am J Obstet Gynecol 194: 664–673.
10. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, et al. (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8: 315–317.
11. Nakagawa O, Ogawa Y, Itoh H, Suga S, Komatsu Y, et al. (1995) Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload. J Clin Invest 96: 1280–1287.
12. Yamahara K, Sone M, Itoh H, Yamashita JK, Yurugi-Kobayashi T, et al. (2008) Augmentation of neovascularization [corrected] in hindlimb ischemia by combined transplantation of human embryonic stem cells-derived endothelial and mural cells. PLoS One 3: e1666.
13. Aggarwal S, Pittenger MF (2005) Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105: 1815–1822.
14. Kikuchi-Taura A, Taguchi A, Kanda T, Inoue T, Kasahara Y, et al. (2012) Human umbilical cord provides a significant source of unexpanded mesenchymal stromal cells. Cytotherapy 14: 441–450.
15. Wei JP, Zhang TS, Kawa S, Aizawa T, Ota M, et al. (2003) Human amnion-isolated cells normalize blood glucose in streptozotocin-induced diabetic mice. Cell Transplant 12: 545–552.
16. Pan HC, Yang DY, Chiu YT, Lai SZ, Wang YC, et al. (2006) Enhanced regeneration in injured sciatic nerve by human amniotic mesenchymal stem cell. J Clin Neurosci 13: 570–575.
17. Bailo M, Soncini M, Vertua E, Signoroni PB, Sanzone S, et al. (2004) Engraftment potential of human amnion and chorion cells derived from term placenta. Transplantation 78: 1439–1448.
18. Rossi D, Pianta S, Magatti M, Sedlmayr P, Parolini O (2012) Characterization of the conditioned medium from amniotic membrane cells: prostaglandins as key effectors of its immunomodulatory activity. PLoS One 7: e46956.
19. Kim SW, Zhang HZ, Guo L, Kim JM, Kim MH (2012) Amniotic mesenchymal stem cells enhance wound healing in diabetic NOD/SCID mice through high angiogenic and engraftment capabilities. PLoS One 7: e41105.
20. Lee JM, Jung J, Lee HJ, Jeong SJ, Cho KJ, et al. (2012) Comparison of immunomodulatory effects of placenta mesenchymal stem cells with bone marrow and adipose mesenchymal stem cells. Int Immunopharmacol 13: 219–224.
21. Miyahara Y, Nagaya N, Kataoka M, Yanagawa B, Tanaka K, et al. (2006) Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction. Nat Med 12: 459–465.
22. Gnecchi M, He H, Liang OD, Melo LG, Morello F, et al. (2005) Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 11: 367–368.

MATERNAL-FETAL MEDICINE

The effects of antenatal corticosteroids therapy on very preterm infants after chorioamnionitis

Ken Miyazaki · Madoka Furuhashi ·
Kaoru Ishikawa · Koji Tamakoshi ·
Tomoaki Ikeda · The Neonatal Research Network Japan

Abstract

Purpose To evaluate the effectiveness of antenatal corticosteroids (AC) therapy on outcomes of very low birthweight infants with histologic chorioamnionitis.

Methods We performed a retrospective analysis of 10,935 single infants born at a gestational age between 22 + 0 and 33 + 6 weeks and birth weight <1,500 g. Clinical data were obtained from the Neonatal Research Network that included the tertiary neonatal intensive care units throughout Japan between 2003 and 2008.

Results Data of 7,896 infants were available for the period 2003–2008 and were included in the analysis. According to logistic regression analysis, AC were significantly associated with reduced mortality [odds ratio (OR) = 0.50; $p < 0.001$], lower incidence of respiratory distress syndrome (OR = 0.72; $p < 0.001$), neonatal seizure (OR = 0.65; $p = 0.003$) and intraventricular hemorrhage (OR = 0.68; $p = 0.001$) in cases after histologic chorioamnionitis compared with the cases had no AC therapy ($n = 3,271$ vs. 4,625). Antenatal corticosteroids were significantly associated with reduced mortality [odds ratio (OR) = 0.60; $p < 0.001$] among the cases without histologic chorioamnionitis.

Conclusion In the retrospective population-based study in Japan, AC exposure was significantly associated with a lower rate of death and neurological morbidity in cases with histologic chorioamnionitis. These outcome data in Japan will be important for further improvement of antenatal practice and care.

Keywords Chorioamnionitis · Antenatal corticosteroids · Outcome · Preterm infants · Very low birthweight infants

K. Miyazaki (✉) · M. Furuhashi
Department of Obstetrics and Gynecology, Japanese Red Cross
Nagoya Daiichi Hospital, 3-15 Michishita-cho, Nakamura-ku,
Nagoya 453-8511, Japan
e-mail: goldencaesar21@yahoo.co.jp

K. Ishikawa
Department of Endowed Chair for Regeneration of Medicine
in Kuwana District, Suzuka University of Medical Science,
Mie, Japan

K. Tamakoshi
Department of Nursing, Nagoya University Graduate School of
Medicine, Nagoya, Japan

T. Ikeda
Department of Obstetrics and Gynecology, Mie University
Graduate School of Medicine, Mie, Japan

Introduction

Maternal administration of antenatal corticosteroids (AC) is effective to decrease respiratory distress syndrome (RDS) and it improves neurological morbidity and mortality in preterm infants [1–4]. AC therapy has become one of common interventions for threatened preterm delivery [1]. However, most obstetricians are concerned about AC administration and fear adverse effects in cases of suspected infection represented by chorioamnionitis [3, 5]. Major guidelines have indicated that the benefits of AC outweigh the infection risk and recommend AC therapy for pregnant women as long as they show no clinical evidence of infection [4, 5]. However, no evidence has been reported that AC make maternal or fetal infections worse [5]. Pregnant women with signs suggestive of chorioamnionitis have been excluded from randomized control trials [1, 6–9] according to the recommendation. To the best of our knowledge, a randomized clinical trial about the effects of

🖄 Springer

AC therapy in cases of chorioamnionitis does not exist; only small observational studies or cohort studies are available on the efficacy of AC therapy in cases of chorioamnionitis [10–14].

Chorioamnionitis is associated with the incidence of preterm birth, especially in spontaneous preterm birth at very low gestation (<30 weeks) [15], and this association increases with decreasing gestational age [13]. The presence and severity of chorioamnionitis have been diagnosed by pathological examinations of the placenta (histologic chorioamnionitis). Although accurate, this histological diagnosis can only be made after birth. Antenatal infection can be diagnosed in various ways from clinical signs such as elevated temperature, increased white blood cell (WBC) counts, and uterine tenderness. Clinicians are concerned about AC therapy, particularly in cases where the mother already has chorioamnionitis.

The most significant morbidities such as intraventricular hemorrhage (IVH), periventricular leukomalacia (PVL), and chronic lung disease (CLD) are associated with infants weight <1,500 g [10, 16]. In previous studies, AC therapy for women in preterm labor at <34 weeks of gestation decreases neonatal problems, including RDS, IVH, and death [2, 3]. Therefore, the efficacy of AC is much more expected for very low birthweight (VLBW) infants.

The purpose of the study was to evaluate the effectiveness of AC therapy for women we could get postnatal information regarding histologic chorioamnionitis on outcomes of VLBW infants by analyzing a large database (the Neonatal Research Network Japan) and to accumulate one of the largest body of evidence at present.

Materials and methods

This was a retrospective analysis of 7,896 single infants born at a gestational age between 22 + 0 and 33 + 6 weeks and birth weights <1,500 g. Clinical data between 2003 and 2008 were obtained from the Neonatal Research Network Japan which collects data on >50 % of neonates born in Japan. All tertiary neonatal units designated by the government participate in this database. 63 Level III perinatal centers out of the 73 participating facilities were registered for the Neonatal Research Network Japan in the year 2008. This database contains information on morbidity and mortality of VLBW infants <1,500 g and born in participating hospitals.

Data for infants who were born alive but died in the delivery room were included. The clinician's perspective on active treatment or withdrawal of care to preterm infants born at 22 and 23 weeks of gestation depended on the status of infants. After 23 weeks of gestation, most clinicians make an effort to save infants [17].

Data were analyzed according to presence of histologic chorioamnionitis. We analyzed the effect of AC therapy on mortality as the main outcome and studied secondary outcomes with neurological morbidities such as neonatal seizure, IVH, PVL, respiratory morbidities such as RDS, CLD, and adverse effects such as sepsis, late-onset adrenal insufficiency, patent ductus arteriosus (PDA), and necrotizing enterocolitis (NEC).

Non-reassuring fetal status (NRFS) was diagnosed when there is persistent bradycardia or recurrent decelerations. The presence and severity of histologic chorioamnionitis were examined on the basis of Blanc's criteria [18, 19]. IVH was reported according to the classification of Papile et al. [20]. PVL was diagnosed by either cranial ultrasonography or head magnetic resonance imaging scan, performed at 2 weeks or later. RDS was diagnosed on the basis of clinical presentation and characteristic radiographic appearance. CLD was diagnosed on the basis of dependency on oxygen supplementation at a corrected age of 28 days. Neonatal sepsis was documented by a positive blood culture. Late-onset adrenal insufficiency was clinically diagnosed by systematic hypotension with oliguria, hyperkalemia, and myocardial dysfunction [21]. PDA was defined as persistence of an open ductus arteriosus after birth with clinical symptoms. NEC was defined according to Bell classification stage II or greater [22]. Neonatal mortality was defined as death of an infant before discharge.

Statistical analysis

Data are presented as means ± standard deviations for continuous data and median and range for ordinal data. Differences between the AC and no-steroid groups were tested using a Chi-square test and t test, as appropriate. Multivariable logistic regression analyses were performed to assess the effect of AC therapy on neonatal mortality and morbidity. Odds ratios or coefficients adjusted for confounding variables and 95 % confidence intervals were calculated. Multivariate logistic regression analysis was performed after adjusting for maternal age, parity, diabetes, preeclampsia, premature rupture of the membranes (PROM), non-reassuring fetal status (NRFS), mode of delivery, gestational age at delivery, and sex of the infant.

Statistical analyses were performed using SPSS version 17.0 (SPSS Inc., Chicago, IL, USA). Statistical tests were considered significant at a p value of <0.05.

Results

A total of 19,226 infants were registered in the database between 2003 and 2008 (Fig. 1). In total, 5,156 infants

Fig. 1 Flow of study population. *Asterisk* some terms are crossover

VLBW infants
n=19,226

8,282 excluded *

Multiple pregnancies   n=5,156
GA ≧34 weeks   n=1,760
Major congenital marformation n=1,189
Transport newborn hospitalization n=1,801

Study population
n=10,944

3048 excluded

unknown GA at delivery   n=8
unknown AC administration   n=1
unknown presence of HCA   n=3,039

Available records †
n=7,896

AC (+)
n=3,271 (41.4%)

AC (-)
n=4,625 (58.6%)

Histologic CA (+)
n=1,336 (16.9%)

Histologic CA (-)
n=1,935 (24.5%)

Histologic CA (+)
n=1,264 (16.0%)

Histologic CA (-)
n=3,361 (42.6%)

were excluded because of multiple pregnancies, 1,189 infants were excluded because of major congenital malformation, and 1,801 infants were excluded because they were born outside participant centers. In study population, 3,039 infants were excluded due to lack of the information about the presence and severity of histologic chorioamnionitis. Data of 7,896 (72.1 %) single infants born at gestational ages between $22 + 0$ and $33 + 6$ weeks were available, of which only 3,271 (41.4 %) received AC therapy.

Maternal and delivery characteristics for the groups are described in Table 1. The AC group had significantly higher rates of PROM ($p < 0.001$), and lower rates of NRFS ($p = 0.02$), higher rates of cesarean delivery ($p = 0.001$), lower gestational age at delivery ($p < 0.001$), and lower birthweight ($p < 0.001$).

As the main outcome, the effect of AC therapy on neonatal mortality is shown in Table 2. The mortality rate was 6.2 and 13.3 % in the AC and no-steroid groups, respectively, in pregnant women with histologic chorioamnionitis.

Similarly, the mortality rate was 5.7 and 9.1 % in the AC and no-steroid groups, respectively, in pregnant women with no histologic chorioamnionitis. In the logistic regression analysis, AC therapy was associated with a significant decrease in mortality of infants whose mothers had histologic chorioamnionitis [adjusted odds ratio (OR), 0.50; 95 % confidence interval (CI); 0.37–0.68; $p < 0.001$].

Regarding neurological morbidities, AC therapy resulted in a significant decrease in neonatal seizures (adjusted OR 0.65; CI 0.44–0.95; $p = 0.03$), IVH (adjusted OR 0.72; CI 0.58–0.89; $p = 0.002$), but no significant association with PVL (adjusted OR 0.74; CI 0.52–1.11; $p = 0.15$) in infants of mothers with histologic chorioamnionitis (Table 2).

The effect of AC therapy on respiratory outcome is shown in Table 2. AC therapy was associated with a significant decrease in RDS in cases of histologic chorioamnionitis (adjusted OR 0.72; CI 0.60–0.85; $p < 0.001$).

AC therapy was associated with a significant decrease in neonatal sepsis in women with histologic chorioamnionitis (adjusted OR 0.72; CI 0.56–0.93; $p = 0.01$). No significant

Table 1 Demographics and baseline characteristics

	Steroid ($n = 3,271$)	No steroid ($n = 4,625$)	P value
Maternal age (years)[a]	31.1 ± 5.2	31.1 ± 5.4	0.67
Parity[a]	0.68 ± 0.86	0.67 ± 0.89	0.77
Diabetes	1.1 %	1.8 %	0.006
Preeclampsia	17.5 %	22.7 %	<0.001
PROM	41.8 %	26.2 %	<0.001
NRFS	25.8 %	27.7 %	0.02
Mode of delivery			0.001
Vaginal	26.8 %	28.5 %	
With manipulation	0.5 %	1.0 %	
Cesarean section	72.7 %	70.5 %	
GA at delivery (weeks)[a]	27.6 ± 2.6	27.8 ± 3.0	<0.001
Birth weight (g)[a]	970.2 ± 290.6	995.7 ± 306.3	<0.001
Male sex	52.8 %	51.2 %	0.11

PROM preterm rupture of membranes, *NRFS* non-reassuring fetal status

[a] Mean ± SD

differences were seen for late-onset adrenal insufficiency, PDA, or NEC in women with histologic chorioamnionitis in the logistic regression analysis (Table 2).

Discussion

The current study was an extremely large population-based cohort study that sought to determine the effectiveness of AC therapy in pregnant women who were diagnosed as histologic chorioamnionitis after delivery.

AC therapy was administered to only 41.4 % of women delivered prematurely. This is low rate of AC use in this high-risk population compared with other countries, because in Japan AC therapy was covered under National Health Insurance since 2009. AC therapy decreased neonatal mortality rate and neurological complications regardless of chorioamnionitis in pregnant women (Table 2). The effect was more apparent in pregnant women with histologic chorioamnionitis than those without them. The decrease in neurological complications with the use of AC therapy might lead to a decrease in mortality rate. Hemorrhage in cases of IVH occurs when venous pressure is elevated [23]. PVL is caused by reactive oxygen toxicity resulting from reperfusion or ischemia/hypoxia occurring in the immature fetal brain [24]. AC therapy stabilizes the hemodynamic parameters of the fetus such as blood pressure [25], prevents congestion, ischemia, or reperfusion damage, thus decreasing neurological complications [26].

We experienced decrease in RDS as a result of AC therapy in pregnant women with histologic chorioamnionitis. Fetuses are reportedly stressed by the presence of intrauterine infection/inflammation such as chorioamnionitis, which thereby accelerates lung maturity by encouraging the secretion of endogenous corticosteroids resulting in the production of surfactant [27]. However, we could find AC therapy decreased RDS in the group with histologic chorioamnionitis. In contrast, AC therapy increased RDS in the group without histologic chorioamnionitis. The finding differs from the trend reported in past reports with respect to RDS [1]. This could be because various factors such as the period from steroid administration to delivery had not been adjusted, and RDS has often been subjectively diagnosed by clinical symptoms other than chest X-ray. CLD tended to increase in infants receiving AC therapy, although not significantly. This result possibly occurred because the mortality rate decreased and a larger number of infants in serious condition required long-term ventilation management, oxygen administration, and artificial nutrition [27].

The current study had several limitations. First, the database used in this study had little information about mothers. Aspects such as the type of corticosteroid used during AC therapy, the number of doses of corticosteroids, the period from corticosteroid administration to delivery, maternal sepsis, and maternal mortality were not studied. Second, we analyzed data from multiple facilities; hence, the timing of AC therapy may have differed depending on the facility. However, since this database is very large, the neonatal information associated with AC therapy obtained in the present study is beneficial.

PROM is a higher risk condition for maternal, fetal, and neonatal infection. Intrauterine infection is strongly associated with PROM and particularly complicates 30–50 % of mid-trimester PROM in previous reports [28, 29]. There have been concerns about promoting this risk because of corticosteroid use. However, some recommendations show that AC therapy for pregnant women with PROM before 32 weeks of gestation is beneficial [4, 7, 8]. In this regard, treatment did not increase the risk of maternal death and infection in a systematic review about AC therapy in pregnancies complicated by PROM [1, 30]. As stated above, administration of corticosteroids to pregnant women who have a higher possibility of intrauterine infection is believed to be acceptable without significant maternal adverse effects.

In future, data including information about mothers must be examined, differences in the effectiveness of AC therapy depending on gestational age, and differences among different steroids, dosage, and other variations in treatments regimes must be studied. The effectiveness of AC therapy must be ascertained in a study of multiple pregnancies. In addition, the data on long-term prognosis of cases included in this study are being analyzed.

Table 2 Effects of antenatal corticosteroid on neonatal outcomes after histologic chorioamnionitis

	Affected/total (%)		Crude OR	Adjusted OR[a]	95 % CI	P value
	Steroid	No steroid				
Neonatal mortality						
Histologic CA(+)	83/1,336 (6.2)	168/1,264 (13.3)	0.43	0.50	0.37–0.68	<0.001
Histologic CA(−)	111/1,935 (5.7)	306/3,361 (9.1)	0.61	0.60	0.47–0.78	<0.001
Overall	194/3,271 (5.9)	474/4,625 (10.2)	0.65	0.56	0.48–0.67	<0.001
Neurological outcomes						
Neonatal seizure						
Histologic CA(+)	49/1,336 (3.7)	80/1,264 (6.3)	0.56	0.65	0.44–0.95	0.03
Histologic CA(−)	49/1,935 (2.5)	122/3,361 (3.6)	0.69	0.69	0.48–0.97	0.03
Overall	98/3,271 (3.0)	202/4,625 (4.4)	0.66	0.56	0.45–0.71	<0.001
IVH						
Histologic CA(+)	224/1,336 (16.8)	294/1,264 (23.3)	0.67	0.72	0.58–0.89	0.002
Histologic CA(−)	217/1,935 (11.2)	433/3,361 (12.9)	0.85	0.87	0.72–1.05	0.14
Overall	441/3,271 (13.3)	727/4,625 (15.7)	0.87	0.74	0.65–0.83	<0.001
PVL						
Histologic CA(+)	56/1,336 (4.2)	66/1,264 (5.2)	0.79	0.74	0.52–1.11	0.15
Histologic CA(−)	61/1,935 (3.2)	125/3,361 (3.7)	0.84	0.80	0.56–1.10	0.18
Overall	117/3,271 (3.6)	191/4,625 (4.1)	0.95	0.83	0.67–1.03	0.09
Respiratory outcomes						
RDS						
Histologic CA(+)	686/1,336 (51.3)	762/1,264 (60.3)	0.70	0.72	0.60–0.85	<0.001
Histologic CA(−)	1,121/1,935 (57.9)	1,759/3,361 (52.3)	1.25	1.17	1.03–1.33	0.02
Overall	1,807/3,271 (55.2)	2,521/4,625 (54.5)	1.16	0.92	0.84–1.00	0.06
CLD						
Histologic CA(+)	727/1,256 (57.9)	621/1,122 (55.3)	1.11	1.05	0.84–1.31	0.66
Histologic CA(−)	685/1,810 (37.8)	866/2,972 (29.1)	1.48	1.38	1.18–1.61	<0.001
Overall	1,412/3,066 (46.1)	1,487/4,094 (36.3)	1.55	1.16	1.04–1.28	0.01
Other outcomes						
Sepsis						
Histologic CA(+)	135/1,336 (10.1)	183/1,264 (14.5)	0.66	0.72	0.56–0.93	0.01
Histologic CA(−)	120/1,935 (6.2)	223/3,361 (6.6)	0.93	0.98	0.76–1.25	0.85
Overall	255/3,271 (7.8)	406/4,625 (8.8)	0.97	0.86	0.74–0.99	0.05
Late-onset adrenal insufficiency						
Histologic CA(+)	163/1,295 (12.6)	149/1,180 (12.6)	0.99	1.05	0.81–1.36	0.70
Histologic CA(−)	156/1,873 (8.3)	241/3,146 (7.7)	1.10	0.92	0.73–1.15	0.47
Overall	319/3,168 (10.1)	390/4,326 (9.0)	1.27	1.02	0.88–1.19	0.77
PDA						
Histologic CA(+)	515/1,336 (38.5)	465/1,264 (36.8)	1.08	1.16	0.97–1.39	0.09
Histologic CA(−)	639/1,935 (33.0)	950/3,361 (28.3)	1.25	1.17	1.02–1.33	0.02
Overall	1,154/3,271 (35.3)	1,415/4,625 (30.6)	1.34	1.13	1.04–1.24	0.01
NEC						
Histologic CA(+)	26/1,336 (1.9)	25/1,264 (2.0)	0.98	1.13	0.63–2.02	0.68
Histologic CA(−)	28/1,935 (1.4)	39/3,361 (1.2)	1.25	1.35	0.81–2.25	0.25
Overall	54/3,271 (1.7)	64/4,625 (1.4)	1.23	1.13	0.82–1.57	0.45

CA chorioamnionitis, *OR* odds ratio, *CI* confidence interval

[a] Adjusted for maternal age, parity, diabetes, preeclampsia, preterm rupture of membrane (PROM), non-reassuring fetal status (NRFS), mode of delivery, gestational age of delivery, birthweight, and sex of the infant

Conclusion

Based on this body of the evidence and the results of our study, we propose that active use of AC therapy is recommended for women with a single pregnancy at the very preterm and even those with chorioamnionitis. These outcome data in Japan will be important for further improvement of antenatal practice and care.

References

1. Brownfoot FC, Gagliardi DI, Bain E, Middleton P, Crowther CA (2013) Different corticosteroids and regimens for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 8:CD006764
2. Crowly P (2002) Prophylactic corticosteroids for preterm birth. Cochrane Database Syst Rev 4:CD000065
3. Crowly PA (1995) Antenatal corticosteroid therapy: a meta-analysis of the randomized trial, 1972–1994. Am J Obstet Gynecol 173:322–335
4. Antenatal corticosteroid therapy for fetal maturation (2011) ACOG Committee Opinion No. 475. American College of Obstetricians and Gynecologists. Obstet Gynecol 117:422–424
5. (1994) Effect of corticosteroids for fetal maturation on perinatal outcomes. NIH Consens Statement. 12:1–24
6. Stutchfield P, Whitaker R, Russell I, Antenatal Steroids for Term Elective Caesarean Section Research Team (2005) Antenatal betamethasone and incidence of neonatal respiratory distress after elective caesarian section: pragmatic randomized trial. BMJ 331:662
7. Murphy KE, Hannah ME, Willan AR, Hewson SA, Ohlsson A, Kelly EN et al (2008) Multiple course of antenatal corticosteroids for preterm birth (MACS): a randomized controlled trial. Lancet 372:2143–2151
8. Qublan H, Malkawi H, Hiasat M, Hindawi IM, Al-Taani MI, Abu-Khait SA et al (2001) The effect of antenatal corticosteroid therapy on pregnancies complicated by premature rupture of membranes. Clin Exp Obstet Gynecol 28:183–186
9. Garite TJ, Rumney PJ, Briggs GG, Harding JA, Nageotte MP, Towers CV et al (1992) A randomized placebo-controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24–28 weeks gestation. Am J Obstet Gynecol 166:646–651
10. Kent A, Lomas F, Hurrion E, Dahlstrom JE (2005) Antenatal steroids may reduce adverse neurological outcome following chorioamnionitis: neurodevelopmental outcome and chorioamnionitis in premature infants. J Paediatr Child Health 41:186–190
11. Baud O, Zupan V, Lacaze-Masmonteil T, Audibert F, Shojaei T, Thebaud B et al (2000) The relationships between antenatal management, the cause of delivery and neonatal outcome in a large cohort of very preterm singleton infants. BJOG 107:877–884
12. Goldenberg RL, Andrews WW, Faye-Petersen OM, Cliver SP, Goepfert AR, Hauth JC (2006) The Alabama Preterm Study: corticosteroids and neonatal outcome in 23- to 32- week newborns with various markers of intrauterine infection. Am J Obstet Gynecol 195:1020–1024
13. Been JV, Rours IG, Kornelisse RF, Passos VL, Kramer BW, Schneider TAJ et al. (2009) Histologic chorioamnionitis, fetal involvement, and antenatal steroids: effects on neonatal outcome in preterm infants. Am J Obstet Gynecol. 201:587.e1-8
14. Been JV, Degraeuwe PL, Kramer BW, Zimmermann LJI (2011) Antenatal steroids and neonatal outcome after chorioamnionitis: a meta-analysis. BJOG 118:113–122
15. Gomez R, Romero R, Edwin SS, David C (1997) Pathogenesis of preterm labor and preterm premature rupture of membranes associated with intraamniotic infection. Infect Dis Clin North Am 11:135–176
16. Fanaroff AA, Stoll BJ, Wright LL, Carlo WA, Ehrenkranz RA et al. (2007) Trends in neonatal morbidity and mortality for very low birthweight infants. Am J Obstet Gynecol. 196:147.e1-8
17. Kusuda S, Fujimura M, Sakuma I, Aotani H, Kabe K, Itani Y et al (2006) Morbidity and mortality of infants with very low birth weight in Japan: center variation. Pediatrics 118:e1130–e1138
18. Lencki SG, Maciulla MB, Eglinton GS (1995) Maternal and umbilical cord serum interleukin levels in preterm labor with clinical chorioamnionitis. Am J Obstet Gynecol 170:1345–1351
19. Blanc WA (1981) Pathology of the placenta, membranes, and umbilical cord in bacterial, fungal, and viral infections in man. In: Naeye RL, Kissane JM, Kaufman N (eds) Perinatal diseases. Internal Academy of Pathology Monograph. Williams & Wilkins, Baltimore, pp 67–132
20. Papile L, Burstein J, Burstein R, Koffler H (1978) Incidence and evolution of subependymal and intraventricular hemorrhage; a study of infants with birth weights less than 1500. J Pediatr 92:5229–5534
21. Ng PC, Lee CH, Lam CWK, Ma KC, Fok TF, Chan IH et al (2004) Transient adrenocortical insufficiency of prematurity and systemic hypotension in very low birthweight infants. Arch Dis Child Fetal Neonatal Ed 89:119–126
22. Bell MJ, Ternberg JL, Feigin RD, Keating JP, Marshall R, Barton L et al (1978) Neonatal necrotizing enterocolitis. Therapeutic decision based upon clinical staging. Ann Surg 187:1–7
23. Moody DM, Brown WR, Challa VR, Blocks SM (1994) Alkaline phosphatase histochemical staining in the study of germinal matrix hemorrhage and brain vascular morphology in a very-low-birth-weight neonate. Pediatr Res 35:424–430
24. Volpe JJ (2001) Neurobiology of periventricular leukomalacia in the preterm infants. Pediatr Res 50:553–562
25. Koenen SV, Mecenas CA, Smith GS, Jenkins S, Nathanielsz PW (2002) Effects of maternal betamethasone administration on fetal and maternal blood pressure and heart rate in the baboon at 0.7 of gestation. Am J Obstet Gynecol 186:812–817
26. Perlman JM (1998) Antenatal glucocorticoids, Magnesium exposure, and the prevention of brain injury of prematurity. Semin Pediatr Neurol 5:202–210
27. Lyon A (2000) Chronic lung disease of prematurity. The role of intra-uterine infection. Eur J Pediatr 159:798–802
28. Yoon BH, Romero R, Park JS, Kim CJ, Kim SH, Choi JH et al (2000) Fetal exposure to an intra-amniotic inflammation and development cerebral palsy at the age of three years. Am J Obstet Gynecol 182:675–681
29. Kurkinen-Raty M, Koivisto M, Jouppila P (1998) Perinatal and neonatal outcome and late pulmonary sequelae in infants born after preterm premature rupture of membranes. Obstet Gynecol 92:408–415
30. Harding JE, Pang J, Knight DB, Liggins GC (2001) Do antenatal corticosteroids help in the setting of preterm rupture of membranes? Am J Obstet Gynecol 184:131–139

C1 Esterase Inhibitor Activity in Amniotic Fluid Embolism

Naoaki Tamura, MD, PhD[1]; Satoshi Kimura, MD[1]; Mustari Farhana[1]; Toshiyuki Uchida, MD, PhD[1];
Kazunao Suzuki, MD, PhD[1]; Kazuhiro Sugihara, MD, PhD[1]; Hiroaki Itoh, MDSc[1];
Tomoaki Ikeda, MD, PhD[2]; Naohiro Kanayama, MD, PhD[1]

AQ1

AQ3 **Introduction:** Amniotic fluid embolism exhibits activation of the complement system and the kallikrein-kinin and coagulofibrinolytic systems. C1 esterase inhibitor is a major inhibitor of C1 esterase and can inhibit plasma kallikrein and also factors XIIa and XIa. Its activity has been shown to be significantly lower in pregnancy and labor than in the nonpregnant state. The purpose of this study was to determine C1 esterase inhibitor activity levels in amniotic fluid embolism.

Methods: This study was retrospectively conducted on 194 singleton pregnant women. One hundred six cases of amniotic fluid embolism had applied to the Japan amniotic fluid embolism registration center in Hamamatsu University School of Medicine between January 2010 and December 2011. In amniotic fluid embolism cases, 85 cases were nonfatal and 21 cases were fatal. Eighty-eight women who delivered without amniotic fluid embolism were regarded as a control. C1 esterase inhibitor activity levels at the onset of amniotic fluid embolism in amniotic fluid embolism cases and at the completion of labor in control cases were measured and compared using the Mann-Whitney U test.

Results: C1 esterase inhibitor activity levels were significantly lower in amniotic fluid embolism patients (30.0% ± 1.8%) than in control women (62.0% ± 2.0%) ($p < 0.0001$). C1 esterase inhibitor activity levels in fatal amniotic fluid embolism cases (22.5% ± 3.4%) were significantly lower than those in nonfatal amniotic fluid embolism cases (32.0% ± 2.1%) ($p < 0.05$).

Conclusions: These results demonstrated that low C1 esterase inhibitor activity levels were closely associated with the pathogenesis of amniotic fluid embolism suggesting that C1 esterase inhibitor activity levels have potential as a prognosis factor of amniotic fluid embolism. (*Crit Care Med* 2014; XX:00–00)

Key Words: amniotic fluid embolism; C1 esterase inhibitor; disseminated intravascular coagulopathy; kallikrein; postpartum hemorrhage; serpin

[1]Department of Obstetrics and Gynaecology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.

[2]Department of Obstetrics and Gynaecology, Mie University School, Mie, Japan.

Amniotic fluid embolism (AFE) is one of the most serious complications of obstetrics, anesthetics, and critical care. Despite earlier recognition and intensive critical care, the mortality of AFE remains high and has been estimated at between 5% and 15% of all maternal deaths (1). Maternal mortality rates due to AFE have been estimated at between 37% and 80% (2, 3). Maternal death has been decreasing year by year in Japan; however, the prevalence of maternal death due to AFE has remained unchanged. The maternal mortality rate due to AFE has increased to 24.3% in Japan (4). AQ4

AFE is recognized as a kind of syndrome characterized by the abrupt onset of hypoxia, hypotension, and disseminated intravascular coagulopathy (DIC) (5). Benson et al (6) reported that maternal complement levels were significantly decreased in AFE. These findings suggested a disorder in the coagulofibrinolytic system as well as the complement system that may play important roles in the pathogenesis of AFE.

We developed the Japan AFE registration system in 2003 and collected clinical data, maternal serum, and uterine tissue from nearly all cases of fatal AFE in Japan (4, 7). Under the system, maternal serum has been applied to determine mainly the levels of specific amniotic fluid complements such as Sialyl Tn and zinc coproporphyrin 1 (8, 9). These clinical and histopathological observations demonstrated that AFE was frequently associated with uterine atony due to angioedema (unpublished data). AQ5

C1 esterase inhibitor (C1INH), belonging to the serpin group/family, is a major inhibitor not only of C1 esterase but also of kallikrein and factors XIIa and XIa (10–12). Its deficiency has been known to be a direct cause of hereditary angioedema (HAE) as well as acquired angioedema (13). Since

<DOI:10.1097/CCM.0000000000000217>

Tamura et al

C1INH has the potential to regulate the coagulofibrinolytic system, complement system, and kallikrein-kinin system, we have become greatly interested in C1INH activity levels in AFE in Japan.

MATERIALS AND METHODS

Definition of AFE

AFE was defined based on the Japan consensus criteria for the diagnosis of AFE based on the United States/United Kingdom criteria as shown in Figure 1 (7, 14). A pathological diagnosis was determined when fetal debris was found in the maternal pulmonary arteries. The diagnosis of nonfatal AFE depended on clinical manifestations and was done when factors B1–B3 were all present, but more than one of the signs and symptoms listed in B1 needed to be present. Consumptive coagulopathy/DIC due to evident etiologies such as abnormal placentation (placental abruption, etc.), trauma during labor and delivery, and severe preeclampsia/eclampsia should be excluded from the criteria.

Patients

The Japan AFE registration system was started in 2003 (7). This system has included the procedure of consent to apply and analyze their clinical data and blood samples. Consent was obtained from patients or patient's family, when physicians regarded their patients with significant symptoms as AFE based on the diagnostic criteria of AFE. Clinical data and serum from nearly all cases of AFE have accumulated in Hamamatsu University School of Medicine. Subjects of the present study were extracted from entry cases in the Japan AFE registration center in Hamamatsu University School of Medicine, Shizuoka, between January 2010 and December 2011. Women with multiple pregnancies, preeclampsia, thrombophilia, preterm labor, uterine disorder such as uterine myoma, and a history of systemic disease were excluded from this study. Cesarean section was carried out due to obstetrical indications, such as breech presentation, history of cesarean section, arrest of labor, and nonreassuring fetal status. Women, who delivered at Hamamatsu University Hospital between April 2011 and September 2011, without AFE and any medical intervention other than

---

The Japan consensus criteria for the diagnosis of AFE

A. Pathological confirmation; A diagnosis is made on the basis of clinical presentation after excluding differential diagnosis and at autopsy in the event of death of the parturient. The diagnosis is confirmed by histochemical studies.

B. Clinical manifestation; The patients has the hallmark clinical manifestations of AFE following 1, 2, and 3:
1. Signs and symptoms: Cardiac arrest/ Respiratory arrest/ Consumptive coagulopathy
2. Onset of all of the signs and symptoms during pregnancy, labor, or cesarean section or within 12 hours of delivery
3. Absence of other illness that could explain the signs and symptoms described above

Figure 1. The Japan consensus criteria for the diagnosis of amniotic fluid embolism (AFE). A pathological diagnosis was determined when fetal debris was found in the maternal pulmonary arteries. The diagnosis of nonfatal AFE depended on clinical manifestations and was done when factors B1–B3 were all present, but more than one of the signs and symptoms listed in B1 needed to be present.

general birth and surgical assistances were analyzed as the control subjects. One hundred six cases of AFE and 88 cases of control were defined (Table 1). Among the AFE cases, 85 cases survived and 21 cases died due to AFE.

Blood Collection and Measurement of C1INH Activity

Blood samples from registered AFE patients were collected at the Japan AFE registration center in Hamamatsu, and serum and plasma samples were then kept at $-30°C$ until use. Time points of blood samples obtained were at onset of and before interventions against AFE. Control blood samples were obtained at the completion of labor. The determination of C1INH activity was performed using the Berichrom C1 inhibitor kit (Siemens Healthcare Diagnostics) according to the manufacturer's instructions. The intra-assay coefficients of variation (CV) ranged between 1.8% and 7.9% and the interassay CV were between 3.2% and 6.6%. We analyzed all the samples at the same time under a blind fashion. In the present study, we demonstrated the measurement of C1INH activity in serum. Furthermore, C1INH activity was measurable in serum as well as plasma; there were no significant differences ($p < 0.0001$, $R^2 = 0.9881$) in the activity level between serum and plasma under the Berichrom C1 inhibitor kit (data not shown).

Approval

Written informed consent was obtained after full explanation of the study. The study was carried out under the approval of the Ethics Committee of Hamamatsu University School of Medicine (Number 24–130 and 25–107), which conforms to the provisions of the Declaration of Helsinki (as revised in Tokyo 2004).

Data Analysis

Values of C1INH activity (%) were presented as the median ± SE. Significant differences were assessed with the Mann-Whitney U test. A p value of less than 0.05 was considered significant.

RESULTS

As shown in Figure 2, C1INH activity levels in the controls and AFE cases were 62.0% ± 2.0% and 30.0% ± 1.8%, respectively. C1INH activity levels in the AFE cases were significantly lower than those in the controls ($p < 0.0001$). C1INH activity levels in fatal and nonfatal AFE cases were 22.5% ± 3.4% and 32.0% ± 2.1%, respectively. A significant difference was observed between the two groups ($p = 0.0121$).

Changes in C1INH activity levels in one survivor case and one case that died due to AFE are shown in Figure 3. Both cases were defined as AFE by the Japan consensus criteria for the diagnosis of AFE shown in Figure 1. C1INH activity levels were potentially very low before the onset of AFE. C1INH activity in the survivor case was at its lowest level at the onset 3 hours after the selective cesarean section due to history of cesarean section when AFE was defined due to the development of DIC. Immediate replacement therapy with FFP successfully increased the activity of C1INH. In the case that died,

AQ6 **TABLE 1. XXX**

AQ7

	Control	Total AFE	Nonfatal AFE	Fatal AFE
No. of subjects	88	106	85	21
Age (yr)	31.0±4.8	33.8±5.8	33.3±5.4	35.6±3.8
Gravida[a]	1.27±1.02	1.64±1.77	1.74±1.82	1.23±1.47
Parity[a]	0.72±0.63	0.83±1.06	0.89±1.12	0.57±0.72
Nulliparous (%)	28 (31.8)	52 (49.0)	41 (48.3)	11 (52.4)
Multiparous (%)	60 (68.2)	54 (51.0)	44 (51.7)	10 (47.6)
Gestational period (d)	273±12	268±19	267±20	270±17
Delivery methods				
Vaginal delivery (%)	60 (68.2)	52 (49.0)	44 (51.7)	10 (47.6)
Cesarean section (%)	28 (31.8)	54 (51.0)	41 (48.3)	11 (52.4)
Blood loss at delivery (mL)				
Vaginal delivery	395±170	4,864±3,039	5,038±3,111	4,097±2,569
Cesarean section	840±279	4,270±2,988	4,314±2,657	4,107±3,961

AFE = amniotic fluid embolism.
[a]Woman without previous history of pregnancy and delivery was determined as gravida 0 and parity 0, respectively.

C1INH activity was also low before the manifestation of AFE symptoms. In this case, amniotic fluid, fetal substance, and gram-positive coccus were observed and autopsy diagnosis was AFE and bacteremia.

DISCUSSION

AFE is an unpredictable and serious disorder of pregnancy characterized by hypotension, hypoxia, and coagulopathy (5). In most pregnant women, the entry of small amounts of amniotic fluid into the maternal circulation may be innocuous; however, such exposure is associated with a fatal outcome in other women. Anaphylactic reactions have been suggested as a concept of AFE to explain such an individual difference in the response to amniotic fluid (2, 15). Benson (6, 16) reported that serum tryptase and urinary histamine increased and complement levels decreased in AFE patients, suggesting that contact and maternal immune activation played important roles in the pathophysiology of AFE.

Clinically, DIC-type postpartum hemorrhage accompanying uterine atony is one of the recognized symptoms of AFE (4, 17). To explain this, coagulation factor XII (FXII) may be responsible for the pathological condition as it is activated by contact with various artificial or biological negatively charged surfaces, resulting not only in blood coagulation but also in the activation of the complement system and kallikrein-kinin system to produce bradykinin (18). We demonstrated that FXII inactivated plasminogen activator inhibitor 1 and enhanced fibrinolysis (19). Interestingly, bradykinin has strong vasodilation effects, a hypotensive effect, and causes an increase in vascular permeability resulting in a hypotonic uterus (20, 21). These findings suggest that FXII activation by contact triggers the subsequent catastrophic chain of AFE. We are continuing to investigate the possible role of FXII in AFE.

C1INH, which is mainly synthesized in hepatocytes and endothelial cells and belongs to serpin family, is a major inhibitor of not only C1 esterase but also FXIIa and kallikrein (11, 12). Its deficiency is known to be a specific cause of HAE (13). Since C1INH is capable of not only inhibiting the complement system but also modulating the coagulofibrinolytic and kallikrein-kinin systems (22, 23), we hypothesized that C1INH was key in the pathophysiology of AFE.

Halbmayer et al (24) reported that basal C1INH activity levels decreased markedly with pregnancy up to labor. Although the mechanism remains unclear, estradiol (E2) was shown to suppress the potential activity of C1INH (25, 26).


Figure 2. C1 esterase inhibitor (C1INH) activity levels in control, amniotic fluid embolism (AFE), nonfatal AFE, and fatal AFE cases. Columns indicate the medians and whiskers represent the minimum and maximum values. Significant differences were $*p < 0.0001$ and $**P = 0.0121$, respectively.

Tamura et al

Figure 3. Chronological changes in C1 esterase inhibitor (C1INH) activity levels in amniotic fluid embolism (AFE) cases. A survivor of AFE (**A**) and a case that died due to the coexistence of AFE with bacteremia (**B**). Potential C1INH activity levels were low before the onset of AFE. In case A, the sudden onset of AFE presented disseminated intravascular coagulopathy (DIC) 3hr after rupture of membrane (ROM) under a selective cesarean section. When AFE was recognized as abnormal coagulopathy, blood replacement therapy was immediately administrated resulting in an increase in C1INH activity levels. In case B, despite intensive care including adequate blood transfusions, C1INH activity levels did not recover. A *dotted line* indicates 70% of C1INH activity. Normal C1INH activity is more than 70%. RCC = , FFP = .

AQ10

The increase in E2 levels during pregnancy may be associated with the decrease in C1INH activity levels in pregnant women. They also observed that C1INH activity levels were significantly lower in preeclampsia patients than in normal pregnant women (24). Increases in C3a and C5a have been reported not only in AFE patients but also in patients with preeclampsia and eclampsia (27), which suggests that the consumption of C1INH is due to activation of the complement system. This may explain the high risk of AFE associated with preeclampsia and eclampsia as risk factors of AFE (28, 29).

The present study demonstrated that C1INH activity levels in AFE cases were significantly lower than those of controls. Furthermore, when we compared fatal cases to nonfatal cases using Pearson chi-square test for C1INH activity less than 25% as a cutoff value almost comparable to "attack of angioedema," there was a significant difference with p equal to 0.026 (degree of freedom 1 and chi-square value 4.956). In addition, the chronological assessment of C1INH activity levels in two AFE patients indicated that their basal C1INH activity levels before delivery and onsets of AFE were also lower at 29% and 12% than that of healthy pregnant controls at 74.3% ± 15.5%

during the third trimester (24). These results suggest that low C1INH activity levels before onset of AFE could be a predictive factor as well as low levels at onset and the persisting low levels of C1INH activity could be a prognostic factor of AFE.

It has been reported that the levels of C1INH may be increased during infection as an acute phase protein, then cleaved and inactivated by neutrophil elastase and bacterial proteases under developing inflammatory conditions due to bacteremia and sepsis resulting in a functional C1INH deficiency (30–32). As demonstrated in the fatal case in Figure 3B, we should note here that not only C1INH consumption under AFE condition but also C1INH inactivation under inflammatory conditions due to bacteremia may be involved in the persistent low levels of C1INH activity (32).

As a treatment for DIC with AFE, the rapid administration of FFP or cryoprecipitate was sufficient to extricate the patient from a critical situation. FFP contains several essential proteins such as ATIII and fibrinogen. One hundred units AQ11 of C1INH are contained in FFP derived from 200 mL blood. Our chronological assessment of C1INH activities in the AFE patient shown in Figure 3A demonstrated that a suited blood transfusion including FFP was able to improve C1INH activity. Clinically, the use of 500–1,500 U of human plasma–derived C1INH concentrates can revert HAE in C1INH-deficient patients (33–35). Since AFE patients certainly have significant lower levels of C1INH activity, similar to a C1INH deficiency, the clinical application of human plasma–derived C1INH concentrates may become one of the promising candidates for the treatment of AFE.

In summary, we reported here that C1INH activity levels were significantly lower in AFE cases, particularly in fatal cases. These results indicate that C1INH activity levels reflect the severity of AFE and can be a prognostic factor of AFE. We speculate that the clinical application of C1INH concentrates will be effective for the treatment of AFE. Although the chronological measurement of C1INH activity was small, our results suggest that pregnant women with potentially low C1INH activity levels may be at a high risk of the onset of AFE. Further clinical studies are required to elucidate the etiological role of C1INH in AFE and determine whether C1INH activity may be a predictive factor of AFE.

REFERENCES

1. Conde-Agudelo A, Romero R: Amniotic fluid embolism: An evidence-based review. *Am J Obstet Gynecol* 2009; 201:445.e1–445.e13
2. Clark SL, Hankins GD, Dudley DA, et al: Amniotic fluid embolism: Analysis of the national registry. *Am J Obstet Gynecol* 1995; 172:1158–1167; discussion 1167–1169
3. Tuffnell DJ: United kingdom amniotic fluid embolism register. *BJOG* 2005; 112:1625–1629
4. Kanayama N, Inori J, Ishibashi-Ueda H, et al: Maternal death analysis from the Japanese autopsy registry for recent 16 years: Significance of amniotic fluid embolism. *J Obstet Gynaecol Res* 2011; 37:58–63
5. Courtney LD: Amniotic fluid embolism. *Obstet Gynecol Surv* 1974; 29:169–177
6. Benson MD, Kobayashi H, Silver RK, et al: Immunologic studies in presumed amniotic fluid embolism. *Obstet Gynecol* 2001; 97:510–514

7. Oi H, Naruse K, Noguchi T, et al: Fatal factors of clinical manifestations and laboratory testing in patients with amniotic fluid embolism. *Gynecol Obstet Invest* 2010; 70:138–144

8. Kanayama N, Yamazaki T, Naruse H, et al: Determining zinc coproporphyrin in maternal plasma–a new method for diagnosing amniotic fluid embolism. *Clin Chem* 1992; 38:526–529

9. Oi H, Kobayashi H, Hirashima Y, et al: Serological and immunohistochemical diagnosis of amniotic fluid embolism. *Semin Thromb Hemost* 1998; 24:479–484

10. Bock SC, Skriver K, Nielsen E, et al: Human C1 inhibitor: Primary structure, cDNA cloning, and chromosomal localization. *Biochemistry* 1986; 25:4292–4301

11. Tosi M: Molecular genetics of C1 inhibitor. *Immunobiology* 1998; 199:358–365

12. Han ED, MacFarlane RC, Mulligan AN, et al: Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. *J Clin Invest* 2002; 109:1057–1063

13. Osler W: Landmark publication from The American Journal of the Medical Sciences: Hereditary angio-neurotic oedema. 1888. *Am J Med Sci* 2010; 339:175–178

14. Benson MD: Current concepts of immunology and diagnosis in amniotic fluid embolism. *Clin Dev Immunol* 2012; 2012:946576

15. Benson MD, Lindberg RE: Amniotic fluid embolism, anaphylaxis, and tryptase. *Am J Obstet Gynecol* 1996; 175:737

16. Benson MD: Nonfatal amniotic fluid embolism. Three possible cases and a new clinical definition. *Arch Fam Med* 1993; 2:989–994

17. Davies S: Amniotic fluid embolism and isolated disseminated intravascular coagulation. *Can J Anaesth* 1999; 46:456–459

18. Schmaier AH: The elusive physiologic role of Factor XII. *J Clin Invest* 2008; 118:3006–3009

19. Tanaka A, Suzuki Y, Sugihara K, et al: Inactivation of plasminogen activator inhibitor type 1 by activated factor XII plays a role in the enhancement of fibrinolysis by contact factors in-vitro. *Life Sci* 2009; 85:220–225

20. Landesman R, Campbell WL, Wilson K: Uterine relaxant properties of bradykinin in vitro. *Nature* 1963; 197:1208–1209

21. Spencer-Gregson RN: Uterine hypotonia. *Br Med J* 1971; 4:301

22. Cugno M, Cicardi M, Bottasso B, et al: Activation of the coagulation cascade in C1-inhibitor deficiencies. *Blood* 1997; 89:3213–3218

23. Schmaier AH, Murray SC, Heda GD, et al: Synthesis and expression of C1 inhibitor by human umbilical vein endothelial cells. *J Biol Chem* 1989; 264:18173–18179

24. Halbmayer WM, Hopmeier P, Mannhalter C, et al: C1-esterase inhibitor in uncomplicated pregnancy and mild and moderate preeclampsia. *Thromb Haemost* 1991; 65:134–138

25. Gordon EM, Ratnoff OD, Saito H, et al: Rapid fibrinolysis, augmented Hageman factor (factor XII) titers, and decreased C1 esterase inhibitor titers in women taking oral contraceptives. *J Lab Clin Med* 1980; 96:762–769

26. Bork K, Barnstedt SE, Koch P, et al: Hereditary angioedema with normal C1-inhibitor activity in women. *Lancet* 2000; 356:213–217

27. Haeger M, Bengtson A, Karlsson K, et al: Complement activation and anaphylatoxin (C3a and C5a) formation in preeclampsia and by amniotic fluid. *Obstet Gynecol* 1989; 73:551–556

28. Kramer MS, Rouleau J, Baskett TF, et al; Maternal Health Study Group of the Canadian Perinatal Surveillance System: Amniotic-fluid embolism and medical induction of labour: A retrospective, population-based cohort study. *Lancet* 2006; 368:1444–1448

29. Abenhaim HA, Azoulay L, Kramer MS, et al: Incidence and risk factors of amniotic fluid embolisms: A population-based study on 3 million births in the United States. *Am J Obstet Gynecol* 2008; 199:49.e1–49.e8

30. Leid RW, Ballieux BE, van der Heijden I, et al: Cleavage and inactivation of human C1 inhibitor by the human leukocyte proteinase, proteinase 3. *Eur J Immunol* 1993; 23:2939–2944

31. Nuijens JH, Eerenberg-Belmer AJ, Huijbregts CC, et al: Proteolytic inactivation of plasma C1-inhibitor in sepsis. *J Clin Invest* 1989; 84:443–450

32. O'Donnell TF Jr, Clowes GH Jr, Talamo RC, et al: Kinin activation in the blood of patients with sepsis. *Surg Gynecol Obstet* 1976; 143:539–545

33. Waytes AT, Rosen FS, Frank MM: Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. *N Engl J Med* 1996; 334:1630–1634

34. Zuraw BL, Busse PJ, White M, et al: Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. *N Engl J Med* 2010; 363:513–522

35. Cicardi M, Levy RJ, McNeil DL, et al: Ecallantide for the treatment of acute attacks in hereditary angioedema. *N Engl J Med* 2010; 363:523–531

Regular Article

Nonsynonymous mutations in three anticoagulant genes in Japanese patients with adverse pregnancy outcomes

CrossMark

Reiko Neki [a,*], Toshiyuki Miyata [b,**], Tomio Fujita [c], Koichi Kokame [b], Daisuke Fujita [d], Shigeyuki Isaka [e], Tomoaki Ikeda [a], Jun Yoshimatsu [a]

[a] Department of Perinatology and Gynecology, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan
[b] Department of Molecular Pathogenesis, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan
[c] Department of Maternal Medicine, Osaka Medical Center and Research Institute for Maternal and Child Health, Izumi, Osaka, Japan
[d] Department of Obstetrics and Gynecology, Osaka Medical College, Takatsuki, Osaka, Japan
[e] Department of Obstetrics and Gynecology, Kaizuka City Hospital, Kaizuka, Osaka, Japan

ARTICLE INFO

ABSTRACT

Background: Hereditary thrombophilias may associate with uteroplacental thrombosis leading to adverse pregnancy outcomes. The present study was conducted to reveal the frequency of the low-frequency thrombophilic protein S K196E mutation, as well as the frequency of very rare nonsynonymous mutations in protein S, protein C, and antithrombin genes, in patients with adverse pregnancy outcomes.
Patients and methods: We enrolled 330 Japanese patients with adverse pregnancy outcomes and divided them into 233 patients with two or more miscarriages and 114 patients with fetal growth restriction (FGR) and/or intrauterine fetal death (IUFD); 17 patients belonged to both groups. We sequenced the entire coding regions of three anticoagulant genes in all 330 patients.
Results: We found that protein S K196E mutation was identified in 4 out of 233 patients with recurrent miscarriage and in 2 out of 114 patients with FGR and/or IUFD. The frequencies of this mutation in these patient groups were not different from that in a Japanese general population. Very rare nonsynonymous mutations were identified in 3.3% (11 out of 330) of patients with adverse pregnancy outcomes.
Conclusions: Although the low-frequency protein S K196E mutation can increase the risk for venous thromboembolism, it did not increase the risk for adverse pregnancy outcomes even in Japanese.

© 2014 Elsevier Ltd. All rights reserved.

Introduction

Approximately 1-5% of pregnant women have a serious adverse pregnancy outcome, such as severe preeclampsia, placental abruption, intrauterine fetal death (IUFD), or severe fetal growth restriction (FGR) [1]. Recurrent miscarriage, defined as two or more miscarriages, is also a significant public health problem for women, and the prevention of these adverse pregnancy outcomes is important for women's health [2]. An estimated 5% of women of reproductive age in general

experience two or more miscarriages [3]. The causes of serious pregnancy outcomes are unknown, but they may be associated with abnormal placental vasculature and disturbances of hemostasis, leading to inadequate maternal-fetal circulation [4]. Therefore, in order to prevent adverse pregnancy outcomes, it will be important to identify the inherited factors related to inadequate maternal-fetal circulation.

Substantial progress has been made in the identification and understanding of inherited hypercoagulable disorders that promote thrombosis, collectively termed inherited thrombophilia [2,5,6]. These include low-frequency mutations, the factor V Leiden mutation, the prothrombin G20210A mutation, and very rare mutations of protein S, protein C, and antithrombin genes. The factor V Leiden mutation and the prothrombin G20210A mutation are modest genetic risk factors for venous thromboembolism and are widely distributed among Caucasians [7] but are not present in the Japanese population [8,9]. Instead, other authors and we have identified a low-frequency thrombophilic mutation, the protein S K196E mutation, as a genetic risk factor for venous thromboembolism with odds ratios between 3.74 and 8.56 in several Japanese populations [10–14]. The prevalence of this mutant allele in the general Japanese population was found to be about 0.009, suggesting a substantial proportion of the Japanese population carries the protein S E-allele

and is at risk of developing deep vein thrombosis [13–15]. This mutation seems to be specific to Japanese, because it has not so far been identified in Chinese, Koreans, or Caucasians [13,15–18].

Hereditary thrombophilia can be explained by low-frequency mutations including factor V Leiden mutation, prothrombin G20210A mutation, and protein S K196E mutation, as well as by very rare mutations causing deficiencies of protein S, protein C, and antithrombin. The former (the low-frequency mutations) have weak effects and the latter have large effects on thrombosis. It is controversial whether there is an association between low-frequency mutations, such as the factor V Leiden mutation and the prothrombin G20210A mutation, and adverse pregnancy outcomes, such as miscarriage, preeclampsia, FGR, and placental abruption [4,19–37].

The present study was conducted to reveal the hypothesis that the mutations predisposing patients to thrombosis in Japanese may be important risk factors for inadequate maternal-fetal circulation that may explain adverse pregnancy outcomes including recurrent miscarriage, FGR, and IUFD. We therefore examined the frequency of the low-frequency protein S K196E mutation, as well as those of very rare nonsynonymous mutations in protein S, protein C, and antithrombin genes, in patients with adverse pregnancy outcomes.

Patients and Methods

Patients and Diagnostic Criteria for Adverse Pregnancy Outcomes

In this prospective observational study, 330 patients who had experienced adverse pregnancy outcomes were enrolled from four tertiary perinatal centers: the National Cerebral and Cardiovascular Center, Osaka Medical Center and Research Institute for Maternal and Child Health, Osaka Medical College, and Kaizuka City Hospital. All of these centers are located in Osaka prefecture, which has the third-largest population out of the 47 prefectures in Japan.

Patients with adverse pregnancy outcomes were classified into two groups: those with recurrent miscarriage (233 patients) and those with FGR and/or IUFD that had occurred after 22 weeks of gestation (114 patients); 17 patients belonged to both groups. We excluded patients with multiple pregnancy. Patients were excluded in a case that patients and the partners had chromosomal abnormalities. Patients with antiphospholipid syndrome, diabetes mellitus, thyroid dysfunction, infectious diseases, and uterine deformity were also excluded. Antiphospholipid syndrome was diagnosed according to the revised classification criteria, requiring at least one of the clinical criteria

(vascular thrombosis or pregnancy morbidity) and at least one of the following laboratory criteria: lupus anticoagulant, anticardiolipin antibody, and anti-β2-glycoprotein-I antibody [38]. Previous miscarriage was defined as pregnancy loss at a gestational age of 22 weeks or less. The definition of miscarriage included documentation of pregnancy by a positive pregnancy test and clinical manifestations of miscarriage (e.g., abdominal pain, cramps, and vaginal bleeding). Recurrent miscarriage was defined as at least two miscarriages. We diagnosed FGR if an ultrasound examination showed a fetus with an estimated fetal weight of less than − 1.5 standard deviation in Japanese at more than 22 weeks of gestation. We also diagnosed IUFD as fetal death at more than 22 weeks of gestation by ultrasound examination. The plasma samples were obtained at least 3 months' postpartum and after at least 3 months without the use of warfarin or oral contraceptives. Protein S anticoagulant activity, free protein S antigen, protein C amidolytic activity, and heparin-dependent antithrombin activity were measured as previously described [39].

The protocol of this study was approved by the Ethics Review Committee of National Cerebral and Cardiovascular Center, Osaka Medical Center and Research Institute for Maternal and Child Health, Osaka Medical College, and Kaizuka City Hospital. Only those who had given written informed consent for genetic analysis were included in the genetic analysis.

DNA Sequencing of Protein S, Protein C, and Antithrombin Genes

We sequenced the entire coding regions of protein S, protein C, and antithrombin genes in 330 patients with adverse pregnancy outcomes. The method of direct sequencing using the 96-capillary 3730xl DNA Analyzer (Applied Biosystems Japan, Tokyo, Japan) was described previously [39]. We have adopted the numbering standards of the Human Genome Variation Society, wherein the A of the ATG of the initiator Met codon is denoted as nucleotide + 1 and the initial Met residue is denoted as amino acid + 1 [40]. The potential impact of a missense mutation on the structure and function was examined using PolyPhen-2 (URL: http://genetics.bwh.harvard.edu/pph2/), a program to predict the functional significance of missense mutations [41].

Statistical Analysis

Statistical analysis was performed using JMP 10 (SAS Institute, Cary, NC, USA). Data are presented as mean ± standard deviation (SD) or the number of patients. Comparisons between groups were analyzed

Table 1
Baseline characteristics of 233 patients with recurrent miscarriage.

	Patients with genetic mutation (n = 13)	Patients without genetic mutation (n = 220)	P value
Age			
years, mean ± SD (range)	35 ± 5 (27–43)	34 ± 4 (25–44)	0.50[†]
No. ≧35 years old (%)	7 (53.8)	97 (43.9)	0.51[‡]
Body mass index, mean ± SD (range)	19.9 ± 1.8 (17.2-22.5)	21.1 ± 2.9 (16.6-30.5)	0.13[†]
Miscarriage			
No. of times, mean ± SD (range)	2.9 ± 0.5 (2–4)	3.3 ± 1.0 (2–9)	0.13[†]
≧3 miscarriages, no. of patients (%)	11 (84.6)	202 (91.4)	0.41[‡]
Number of mutation carriers			
Protein S mutation	6*	0	
(protein S K196E mutation)	(4*)	(0)	
Protein C mutation	4	0	
Antithrombin mutation	3	0	
Other complications of pregnancy or infant, no.			
FGR and/or IUFD	1	16	
Preeclampsia	0	1	
Eclampsia	0	1	
HELLP syndrome	0	2	
Placental abruption	0	1	

SD, Standard deviation; FGR, fetal growth restriction; IUFD, intrauterine fetal death; HELLP, hemolysis, elevated liver enzymes, and low platelets.
*One patient was a compound heterozygote with protein S K196E and T630I mutations. [†]t-test. [‡]chi-square test.

Table 2
Baseline characteristics of 114 patients with FGR and/or IUFD.

	Patients with genetic mutation (n = 4)	Patients without genetic mutation (n = 110)	P value
Age			
years, mean ± SD (range)	34 ± 7 (28–43)	33 ± 5 (18–48)	0.87*
no. ≧35 years old (%)	1 (25)	35 (31)	0.78[†]
Body mass index, mean ± SD (range)	22.7 ± 4.1 (19.8-28.6)	21.0 ± 3.0 (13.7-29.6)	0.27*
FGR and/or IUFD			
No. of times, mean ± SD (range)	1.5 ± 0.6 (1–2)	1.4 ± 0.7 (1–5)	0.77*
≧3 FGR and/or IUFD, no. of patients (%)	0	6 (5.4%)	0.63[†]
Number of mutation carriers			
Protein S mutation	3	0	
(protein S K196E mutation)	(2)	(0)	
Protein C mutation	1	0	
Antithrombin mutation	0	0	
Other complications of pregnancy or infant, no.			
Recurrent miscarriage	1	16	
Gestational hypertension	1	10	
Preeclampsia	0	2	
HELLP syndrome	0	3	
Placental abruption	0	5	
Deep vein thrombosis	0	1	
Sudden infant death syndrome	0	1	

SD, Standard deviation; FGR, fetal growth restriction; IUFD, intrauterine fetal death; HELLP, hemolysis, elevated liver enzymes, and low platelets. *t-test. [†]chi-square test.

by Student's t-test. Categorical variables were evaluated by the chi-square test. P-values <0.05 were considered significant.

Results

We enrolled 330 patients with adverse pregnancy outcomes, including 233 patients with recurrent miscarriage and 114 patients with FGR and/or IUFD; 17 patients belonged to both groups (Tables 1, 2). The patients with more than three miscarriages were 213 patients out of 233 (Table 1).

The sequencing of the coding regions of the protein S, protein C, and antithrombin genes in 233 patients with recurrent miscarriage identified three missense mutations in the protein S gene in 6 cases, three missense mutations in the protein C gene in 4 cases, and two missense mutations in 2 cases and one amino acid deletion in 1 case in the antithrombin gene (Table 3). One patient had two mutations (K196E and T630I) in the protein S gene. Among the mutations, there were three

Table 3
Nonsynonymous mutations identified in protein S, protein C, and antithrombin genes in 233 patients with recurrent miscarriage.

Patient	cDNA*	Region	Amino acid change	Domain	Prediction of possible impact of an amino acid substitution[†]	Protein S[‡], Protein C[§], or Antithrombin[¶] activity, %	Protein S[‡], Protein C[§], or Antithrombin[¶] activity, during pregnancy, %	Free protein S antigen, %	Age	No. of miscarriages	No. previous live births	Body mass index	Family history of thrombo-embolism	Other complications of pregnancy
Protein S gene														
Case 1	c.586A > G	Exon 6	K196E	EGF2	Benign	n.d.	34[‡]	39**	27	3	1	19.3	None	None
	c.1889C > T	Exon 15	T630I	SHBG	Probably damaging									
Case 2	c.586A > G	Exon 6	K196E	EGF2	Benign	54[‡]	n.d.	71	43	3	1	19.5	None	None
Case 3	c.586A > G	Exon 6	K196E	EGF2	Benign	57[‡]	n.d.	61	34	3	0	18.3	None	None
Case 4	c.586A > G	Exon 6	K196E	EGF2	Benign	28[‡]	n.d.	59	34	4	0	22.4	None	None
case 5	c.1334G > A	Exon 12	R445H	SHBG	Possibly damaging	70[‡]	n.d.	64	37	3	0	21.1	None	None
Case 6	c.1889C > T	Exon 15	T630I	SHBG	Probably damaging	66[‡]	n.d.	70	36	3	0	18.6	None	None
Protein C gene														
Case 7	c.1066C > T	Exon 9	R356C	SPD	Probably damaging	n.d.	76[§]	–	35	4	1	21.9	None	None
Case 8	c.983G > A	Exon 9	R328H	SPD	Probably damaging	114[§]	n.d.	–	43	3	0	19.8	None	FGR/IUFD[††]
Case 9	c.1075G > A	Exon 9	V359I	SPD	Benign	131[§]	n.d.	–	30	3	0	17.7	None	None
Case 10	c.983G > A	Exon 9	R328H	SPD	Probably damaging	47[§]	n.d.	–	33	3	0	18.8	None	None
Antithrombin gene														
Case 11	c.181_183delGAA	Exon 2	K61del	–		n.d.	104[¶]	–	31	3	0	21.5	None	None
Case 12	c.442 T > C	Exon 3	S148P		Benign	58[¶]	40[¶]	–	35	2	1	17.2	Farther[‡‡]	None
Case 13	c.1277C > T	Exon 7	S426L		Probably damaging	101[¶]	116[¶]	–	35	2	2	22.5	None	None

EGF2, epidermal growth factor-like domain 2; SHBG, sex hormone-binding globulin-like domain; SPD, serine protease domain; n.d., not determined; FGR, fetal growth restriction; IUFD, intrauterine fetal death. *position from A of initial ATG in cDNA, [†]Polyphen-2 prediction [41], [‡]protein S anticoagulant activity, [§]protein C amidolytic activity, [¶]antithrombin activity, **23 weeks of gestation during pregnancy, [††]37 weeks of gestation, [‡‡]deep vein thrombosis and pulmonary thromboembolism.

Table 4

Nonsynonymous mutations identified in proteins S and C in 114 patients with FGR and/or IUFD.

Patient	cDNA*	Region	Amino acid change	Domain	Prediction of possible impact of an amino acid substitution†	Protein S† or Protein C§ activity, %	Protein S activity, during pregnancy, %	Free protein S antigen, %	Age	Gravida	Parity	No. of miscarriages	No. previous live births	Body mass index	Family history of thrombo-embolism	Other complications of pregnancy
Protein S gene																
Case 1	c.586A > G	Exon 6	K196E	EGF2	Benign	57†	n.d.	82	33	1	1	0	1	22.4	none	GH
Case 2	c.586A > G	Exon 6	K196E	EGF2	Benign	85†	n.d.	74	30	1	1	0	1	28.6	none	none
Case 3	c.1889C > T	Exon 15	T630I	SHBG	Probably damaging	n.d.	31	36§	28	2	2	0	2	20.1	none	none
Protein C gene																
Case 4**	c.983G > A	Exon 9	R328H	SPD	Probably damaging	114§	–	–	43	4	1	3	0	19.8	none	Recurrent miscarriage

FGR, fetal growth restriction; IUFD, intrauterine fetal death; EGF2, epidermal growth factor-like domain 2; SHBG, sex hormone-binding globulin-like domain; SPD, serine protease domain; n.d., not determined; GH, gestational hypertension.
*position from A of initial ATG in cDNA, †Polyphen-2 prediction [41], ‡protein S anticoagulant activity, §protein C amidolytic activity, ¶26 weeks of gestation during pregnancy, **same patient as case 8 in Table 3.

recurrent mutations: the K196E mutation in the protein S gene in 4 patients, the T630I mutation in the protein S gene in 2 patients, and the R328H mutation in the protein C gene in 2 patients. Among the three recurrent mutations, as previously described, the K196E mutation in the protein S gene is the most common thrombophilic mutation in the Japanese population [10–15].

The sequencing of the coding regions of three genes in 114 patients with FGR and/or IUFD identified two missense mutations in the protein S gene in 3 cases and one missense mutation in the protein C gene in 1 case (Table 4). Two patients carried the K196E mutation in the protein S gene and one had the T630I mutation in the protein S gene. One patient had the R328H mutation in the protein C gene. None of the 114 patients with FGR and/or IUFD had nonsynonymous mutations in the antithrombin gene.

Taking together the results for all 330 patients, the nonsynonymous mutations were identified in 13 out of 233 patients with recurrent miscarriage (frequency: 0.056) and in 4 out of 114 patients with FGR and/or IUFD (frequency: 0.035) (Table 5). Thus, 16 out of 330 patients with adverse pregnancy outcomes (frequency: 0.048) had nonsynonymous mutations in three natural anticoagulant genes.

As described above, the protein S K196E mutation was identified in multiple patients. The protein S K196E mutation was identified in 4 out of 233 patients with recurrent miscarriage (frequency: 0.017) and in 2 out of 114 patients with FGR and/or IUFD (frequency: 0.018). We have previously obtained a frequency of the protein S K196E mutation in a Japanese general population in Osaka prefecture where all 4

Table 5

Number of patients with adverse pregnancy outcomes carrying genetic mutations in three anticoagulant genes.

Gene mutation	Number of patients		
	Recurrent miscarriage (n = 233)*	FGR and/or IUFD (n = 114)*	Total (n = 330)
Protein S K196E mutation	4†	2	6†
Protein S mutation excluding K196E	3†	1	4†
Protein C mutation‡	4	1	4
Antithrombin mutation	3	0	3
Total	13	4	16
Frequency	0.056 (13/233)	0.035 (4/114)	0.048 (16/330)
Frequency, excluding protein S K196E mutation	0.043 (10/233)	0.018 (2/114)	0.033 (11/330)

FGR, fetal growth restriction; IUFD, intrauterine fetal death.*Seventeen patients had both recurrent miscarriage and FGR and/or IUFD. †One patient had protein S K196E and T630I mutations. ‡One patient with recurrent miscarriage and FGR and/or IUFD had protein C mutation.

hospitals participated in the present study are located. In that study, the protein S K196E mutation was identified in 1.8% of Japanese (66 out of 3651) [11]. The frequencies of this mutation in the two disease groups, recurrent miscarriage and FGR and/or IUFD, were not different from that in the Japanese general population (p = 0.941, the general population vs. the recurrent miscarriage group; p = 0.982, the general population vs. the FGR and/or IUFD group). Once those patients with protein S K196E mutation were excluded, remaining very rare nonsynonymous mutations were identified in 10 out of 233 patients with recurrent miscarriage (frequency: 0.043) and in 2 out of 114 patients with FGR and/or IUFD (frequency: 0.018) (Table 5). One patient with protein C mutation had both recurrent miscarriage and FGR and/or IUFD. Thus, 11 out of 330 patients with adverse pregnancy outcomes (frequency: 0.033) had nonsynonymous mutations in three natural anticoagulant genes, excluding the protein S K196E mutation (Table 5).

Discussion

To examine the association of hereditary thrombophilia with adverse pregnancy outcomes, we sequenced three anticoagulant genes, protein S, protein C, and antithrombin, in 330 Japanese women with adverse pregnancy outcomes including recurrent miscarriage, FGR, and IUFD. We found that the protein S K196E mutation was identified in 1.7% of patients with recurrent miscarriage and in 1.8% of patients with FGR and/or IUFD and these frequencies were not different from that obtained in the Japanese general population in Osaka area (1.8%, 66 out of 3651) [11] where all 4 hospitals participated in the present study are located. Thus, the protein S K196E mutation was not related to adverse pregnancy outcomes. The results are in contrast to that obtained in patients with deep vein thrombosis. In Japanese patients with deep vein thrombosis, the protein S K196E mutation was identified in 8.7% of the patients (15 out of 173) [42].

In the present study, we identified very rare nonsynonymous mutations in three genes in 3.3% of patients with adverse pregnancy outcomes. Thus, carriers with very rare mutations were not dominant in patients with adverse pregnancy outcomes, indicating that the contributions of the very rare mutations of these three genes to the development of adverse pregnancy outcomes were likely weak. In Japanese patients with deep vein thrombosis, 23% (40 out of 173) carried at least one very rare nonsynonymous mutation in the three genes [42].

In conclusion, we collected 330 Japanese women with adverse pregnancy outcomes, including recurrent miscarriage, FGR, and IUFD, and sequenced protein S, protein C, and antithrombin genes. This is the first effort to sequence three anticoagulant genes in patients with adverse pregnancy outcomes. We found that protein S K196E mutation was identified in patients with adverse pregnancy outcomes with the

similar frequency to that obtained in the Japanese general population. We found that very rare nonsynonymous mutations in three genes were only found in 3.3% of patients with adverse pregnancy outcomes. Our study has a limitation. The patients were collected from four tertiary perinatal centers, all located in the Osaka area. To generalize our findings, more patients should be collected from across Japan.

Conflict of Interest Statement

The authors report no conflicts.

Funding Sources

Acknowledgments

References

[1] Sibai BM. Thrombophilias and adverse outcomes of pregnancy–what should a clinician do? N Engl J Med 1999;340:50–2.

[2] Bennett SA, Bagot CN, Arya R. Pregnancy loss and thrombophilia: the elusive link. Br J Haematol 2012;157:529–42.

[3] Blumenfeld Z, Brenner B. Thrombophilia-associated pregnancy wastage. Fertil Steril 1999;72:765–74.

[4] Practice bulletin no. 113: inherited thrombophilias in pregnancy. Obstet Gynecol 2010;116:212–22.

[5] Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet 1999;353: 1258–65.

[6] Pabinger I, Vormittag R. Thrombophilia and pregnancy outcomes. J Thromb Haemost 2005;3:1603–10.

[7] Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995;346: 1133–4.

[8] Fujimura H, Kambayashi J, Monden M, Kato H, Miyata T. Coagulation factor V Leiden mutation may have a racial background. Thromb Haemost 1995;74:1381–2.

[9] Miyata T, Kawasaki T, Fujimura H, Uchida K, Tsushima M, Kato H. The prothrombin gene G20210A mutation is not found among Japanese patients with deep vein thrombosis and healthy individuals. Blood Coagul Fibrinolysis 1998;9:451–2.

[10] Kinoshita S, Iida H, Inoue S, Watanabe K, Kurihara M, Wada Y, et al. Protein S and protein C gene mutations in Japanese deep vein thrombosis patients. Clin Biochem 2005;38:908–15.

[11] Kimura R, Honda S, Kawasaki T, Tsuji H, Madoiwa S, Sakata Y, et al. Protein S-K196E mutation as a genetic risk factor for deep vein thrombosis in Japanese patients. Blood 2006;107:1737–8.

[12] Ikejiri M, Wada H, Sakamoto Y, Ito N, Nishioka J, Nakatani K, et al. The association of protein S Tokushima-K196E with a risk of deep vein thrombosis. Int J Hematol 2010;92:302–5.

[13] Miyata T, Hamasaki N, Wada H, Kojima T. More on: racial differences in venous thromboembolism. J Thromb Haemost 2012;10:319–20.

[14] Yin T, Miyata T. Dysfunction of protein C anticoagulant system, main genetic risk factor for venous thromboembolism in Northeast Asians. J Thromb Thrombolysis 2014;37:56–65.

[15] Miyata T, Kimura R, Kokubo Y, Sakata T. Genetic risk factors for deep vein thrombosis among Japanese: importance of protein S K196E mutation. Int J Hematol 2006;83: 217–23.

[16] Pecheniuk NM, Elias DJ, Xu X, Griffin JH. Failure to validate association of gene polymorphisms in EPCR, PAR-1, FSAP and protein S Tokushima with venous thromboembolism among Californians of European ancestry. Thromb Haemost 2008;99:453–5.

[17] Liu W, Yin T, Okuda H, Harada KH, Li Y, Xu B, et al. Protein S K196E mutation, a genetic risk factor for venous thromboembolism, is limited to Japanese. Thromb Res 2013;132:314–5.

[18] Kimura R, Sakata T, Kokubo Y, Okamoto A, Okayama A, Tomoike H, et al. Plasma protein S activity correlates with protein S genotype but is not sensitive to identify K196E mutant carriers. J Thromb Haemost 2006;4:2010–3.

[19] Preston FE, Rosendaal FR, Walker ID, Briet E, Berntorp E, Conard J, et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996;348:913–6.

[20] Kupferminc MJ, Eldor A, Steinman N, Many A, Bar-Am A, Jaffa A, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999;340:9–13.

[21] Martinelli I, Taioli E, Cetin I, Marinoni A, Gerosa S, Villa MV, et al. Mutations in coagulation factors in women with unexplained late fetal loss. N Engl J Med 2000;343:1015–8.

[22] Infante-Rivard C, Rivard GE, Yotov WV, Genin E, Guiguet M, Weinberg C, et al. Absence of association of thrombophilia polymorphisms with intrauterine growth restriction. N Engl J Med 2002;347:19–25.

[23] Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003;361:901–8.

[24] Kovalevsky G, Gracia CR, Berlin JA, Sammel MD, Barnhart KT. Evaluation of the association between hereditary thrombophilias and recurrent pregnancy loss: a meta-analysis. Arch Intern Med 2004;164:558–63.

[25] Dudding TE, Attia J. The association between adverse pregnancy outcomes and maternal factor V Leiden genotype: a meta-analysis. Thromb Haemost 2004;91:700–11.

[26] Franchi F, Cetin I, Todros T, Antonazzo P, de Santis MS Nobile, Cardaropoli S, et al. Intrauterine growth restriction and genetic predisposition to thrombophilia. Haematologica 2004;89:444–9.

[27] Verspyck E, Borg JY, Le Cam-Duchez V, Goffinet F, Degre S, Fournet P, et al. Thrombophilia and fetal growth restriction. Eur J Obstet Gynecol Reprod Biol 2004;113:36–40.

[28] Lissalde-Lavigne G, Fabbro-Peray P, Cochery-Nouvellon E, Mercier E, Ripart-Neveu S, Balducchi JP, et al. Factor V Leiden and prothrombin G20210A polymorphisms as risk factors for miscarriage during a first intended pregnancy: the matched case–control 'NOHA first' study. J Thromb Haemost 2005;3:2178–84.

[29] Dizon-Townson D, Miller C, Sibai B, Spong CY, Thom E, Wendel Jr G, et al. The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus. Obstet Gynecol 2005;106:517–24.

[30] Dudding T, Heron J, Thakkinstian A, Nurk E, Golding J, Pembrey M, et al. Factor V Leiden is associated with pre-eclampsia but not with fetal growth restriction: a genetic association study and meta-analysis. J Thromb Haemost 2008;6:1869–75.

[31] Kist WJ, Janssen NG, Kalk JJ, Hague WM, Dekker GA, de Vries JI. Thrombophilias and adverse pregnancy outcome - A confounded problem! Thromb Haemost 2008;99: 77–85.

[32] Scifres CM, Macones GA. The utility of thrombophilia testing in pregnant women with thrombosis: fact or fiction? Am J Obstet Gynecol 2008;199(344):e1–7.

[33] Rodger MA, Betancourt MT, Clark P, Lindqvist PG, Dizon-Townson D, Said J, et al. The association of factor V leiden and prothrombin gene mutation and placenta-mediated pregnancy complications: a systematic review and meta-analysis of prospective cohort studies. PLoS Med 2010;7:e1000292.

[34] Silver RM, Zhao Y, Spong CY, Sibai B, Wendel Jr G, Wenstrom K, et al. Prothrombin gene G20210A mutation and obstetric complications. Obstet Gynecol 2010;115: 14–20.

[35] Lykke JA, Bare LA, Olsen J, Lagier R, Arellano A, Tong C, et al. Thrombophilias and adverse pregnancy outcomes: Results from the Danish National Birth Cohort. J Thromb Haemost 2012;10:1320–5.

[36] Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001;344:1222–31.

[37] Marik PE, Plante LA. Venous thromboembolic disease and pregnancy. N Engl J Med 2008;359:2025–33.

[38] Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295–306.

[39] Neki R, Fujita T, Kokame K, Nakanishi I, Waguri M, Imayoshi Y, et al. Genetic analysis of patients with deep vein thrombosis during pregnancy and postpartum. Int J Hematol 2011;94:150–5.

[40] Antonarakis SE. Recommendations for a nomenclature system for human gene mutations. Nomenclature Working Group. Hum Mutat 1998;11:1–3.

[41] Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010;7:248–9.

[42] Miyata T, Sato Y, Ishikawa J, Okada H, Takeshita S, Sakata T, et al. Prevalence of genetic mutations in protein S, protein C and antithrombin genes in Japanese patients with deep vein thrombosis. Thromb Res 2009;124:14–8.

Factors contributing to mortality and morbidity in pregnancy-associated intracerebral hemorrhage in Japan

Jun Yoshimatsu[1], Tomoaki Ikeda[2], Shinji Katsuragi[3], Kazuo Minematsu[4], Kazunori Toyoda[4], Kazuyuki Nagatsuka[5], Hiroaki Naritomi[5], Susumu Miyamoto[6], Koji Iihara[6], Haruko Yamamoto[7] and Yasumasa Ohno[8]

[1]Department of Perinatology and Gynecology, National Cerebral and Cardiovascular Center, [2]Department of Obstetrics and Gynecology, Mie University, Osaka, [3]Department of Obstetrics and Gynecology, Sakakibara Heart Institute, Tokyo, Departments of [4]Cerebrovascular Medicine, [5]Neurology, [6]Neurosurgery, [7]Advanced Medical Technology Development, National Cerebral and Cardiovascular Center, Suita, and [8]Ohno Women's Clinic, Iwakura, Japan

Abstract

Aim: The aim of this study was to analyze the causes and outcomes for intracerebral hemorrhage (ICH) occurring during pregnancy and postnatally.

Material and Methods: A nationwide study of pregnancy-related ICH in Japan was performed. We contacted 1582 facilities to identify women with ICH in pregnancy or postnatally between 1 January 2006 and 31 December 2006. A total of 1012 facilities (70%) responded with completed questionnaires. Risk factors for ICH, neurological features, onset to diagnosis time (O–D time), and obstetric data were recorded.

Results: Thirty-eight cases of pregnancy-associated ICH were identified, corresponding to 3.5 per 100 000 deliveries. There were seven maternal deaths, giving a case mortality rate of 18.4%. Pre-eclampsia was identified in 10 cases (26.3%) and hemolysis elevated liver enzymes and low platelet count (HELLP) syndrome was present in five. There were four cases (10.5%) with Moyamoya disease and seven (18.4%) with arteriovenous malformation. HELLP syndrome and moderately or severely disturbed consciousness at disease onset were significantly associated with a poor outcome (modified Rankin Scale ≥3). Pre-eclampsia, HELLP syndrome and O–D time >3 h were significantly associated with maternal mortality.

Conclusion: Early diagnosis may prevent maternal death, even in severe cases of pregnancy-related ICH. However, maternal–fetal care centers do not always have full-time neurosurgeons or diagnostic imaging tools suitable for diagnosis of ICH. Thus, a network should be established between maternity centers and neurosurgery departments with computed tomography or magnetic resonance imaging available at all times. We recommend transferal of pregnant women with neurological symptoms to a regional facility that is equipped to treat such patients.

Key words: cerebrovascular disease, morbidity, mortality, postnatally, pregnancy.

Introduction

Intracerebral hemorrhage (ICH) is a subtype of intracranial hemorrhage that occurs within the brain tissue itself and is a serious medical emergency because it can increase intracranial pressure. The mortality rate for ICH is 13–23% in Japan, which is the second highest among subtypes of cerebral stroke, after subarachnoid hemorrhage.[1] ICH is an infrequent but severe complication in pregnancy. The absolute risk is small, but ICH complicated with pregnancy has a significant impact on maternal and fetal outcome. Pregnancy-related ICH

1267

has an estimated mortality of 9–38%[2-6] and survivors may suffer profound and permanent disability. An association of ICH with pregnancy has long been recognized and many factors have been proposed to be partly responsible for the recent increase in the incidence of this condition. Nagaya *et al.*[7] examined factors contributing to maternal mortality in the Japanese population in 1991 and 1992, and identified 27 maternal deaths due to intracranial hemorrhage, which was the second most common cause of maternal mortality after obstetrical hemorrhage.

The incidence, cause, and outcome of ICH in pregnancy or postnatally are poorly understood. Furthermore, the characteristics of pregnancy-associated ICH in the Japanese population may differ from those in other countries, as the Hisayama study[8] found that the incidence of ICH in the general Japanese population was much higher than that in Western countries. A high prevalence of small-artery cerebrovascular lesions may be responsible for the high prevalence of ICH in Asians. The higher incidence of Moyamoya disease in Japan may be another reason for the high incidence of pregnancy-associated ICH.[9] Moyamoya disease is characterized by progressive stenosis of the terminal portion of the internal carotid artery and is a known cause of cerebral stroke, which is mainly caused by hemodynamic stress of pregnancy on fragile Moyamoya vessels. With this background, the aim of this study was to analyze the causes and outcomes for ICH occurring during pregnancy and postnatally.

Methods

A nationwide study of pregnancy-related ICH was performed in Japan. In December 2007, we contacted obstetricians and neurosurgeons at 1582 facilities to identify cases of ICH that occurred in association with pregnancy or postnatally (until 1 year after delivery) from 1 January to 31 December 2006. The survey sent to each facility is shown in Figure 1. To check for cases that may have eluded identification, we also contacted neurology, neurosurgery and intensive care departments. A total of 1012 facilities (70%) responded with completed questionnaires. We asked each facility to identify from its records all patients with an ICH occurring during pregnancy or postnatally. Risk factors for ICH, neurological features, onset to diagnosis time (O–D time) and obstetric data were recorded. In all patients, ICH was verified by brain computed tomography (CT) or magnetic resonance imaging (MRI). Global outcome at discharge was assessed using the

modified Rankin Scale (mRS),[10] with 0–2 defined as a good outcome, 3–5 as a poor outcome, and 6 as death. The consciousness level was measured by the Japan Coma Scale (JCS).[11] In an attempt to further define the epidemiology of ICH in pregnancy, we undertook an analysis of this disease using the vital statistics database of the Ministry of Health, Labour and Welfare (MHLW), which is the largest clinical database available in Japan.

The primary aim of the study was to identify risk factors for maternal death related to ICH. Univariate logistic regression analysis was performed using six factors: maternal age ≥ 35 years old, pre-eclampsia, HELLP syndrome, moderate to severe disturbed consciousness (JCS II to III) at onset, interval between onset and diagnosis ≥3 h, and history of neurosurgery. These six factors were chosen because they frequently appear in case reports of fatal maternal ICH. Statistical procedures were performed using spss version 11. Univariate logistic regression analysis was performed to identify factors of maternal death related to ICH. The study was approved by the institutional review committee.

Results

Thirty-eight cases of pregnancy-associated ICH were identified out of a total of 1 092 674 deliveries in 2006. These 38 cases were reported from 31 facilities, mostly in urban areas. Seven facilities reported two cases and 27 of the facilities were tertiary referral centers. These findings correspond to 3.5 cases of pregnancy-associated ICH per 100 000 deliveries. There were seven maternal deaths, giving a case mortality rate of 18.4%. Overall maternal death in 2006 occurred at a rate of 0.8 per 100 000 deliveries (calculated using the 2006 vital statistics of the MHLW of Japan). The incidence and mortality rates of ICH at the ages of 15–19, 20–24, 25–29, 30–34, 35–39 and 40–44 years were 6.3, 0.8, 3.9, 3.9, 5.9 and 18.5, and 0.0, 0.0, 0.3, 0.7, 1.7 and 0.0 per 100 000 deliveries, respectively. The mean age of pregnant women with ICH was 31.5 years old (range: 19–43 years old). Pregnancy-associated ICH was highest in the 40–44 years age group. The odds ratio for the incidence of pregnancy-associated ICH in women aged ≥35 years old was 1.9 (95% confidence interval [CI]: 1.0–3.9). Mortality was highest in the 35–39-years age group.

Baseline demographic variables and clinical characteristics are shown in Table 1. ICH developed in twice as many primiparous women as multiparous women